- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.02. | XSpray Pharma AB: Interim Report Fourth Quarter 2023 | 204 | GlobeNewswire (Europe) | October-December 2023, GroupNet sales amounted to SEK 0 thousand (0)Loss before tax amounted to SEK -54,513 thousand (-55,220)Earnings per share before dilution amounted to SEK -1.85 (-2.48)Cash flow... ► Artikel lesen | |
| 12.02. | After rejection, FDA re-accepts Xspray's application for would-be rival to BMS' Sprycel | 9 | FiercePharma | ||
| 12.02. | FDA Accepts Xspray Pharma's NDA-resubmission for Dasynoc - PDUFA Date set to 31 July 2024 | 233 | Business Wire | Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY): The U.S. Food and Drug Administration (FDA) has accepted the resubmission of Xspray Pharma's New Drug Application (NDA) for Dasynoc, following... ► Artikel lesen | |
| 21.11.23 | Xspray Pharma AB: Xspray Pharma's XS003 Achieves Superior Bioavailability Milestone, Matching TASIGNA at Reduced Dosage | 368 | Business Wire | XS003, an amorphous non-crystalline nilotinib, designed to overcome therapeutic limitations of the currently available crystalline formulation of nilotinib (TASIGNA®), is the second protein kinase... ► Artikel lesen | |
| 08.11.23 | Xspray Pharma AB: DASYNOC Uptake into the Blood Remains Consistent When Taken with Omeprazole, Whereas SPRYCEL Uptake is Significantly More Impaired than Previously Understood | 396 | Business Wire | DASYNOC (Xspray's low dose, amorphous, non-crystalline, dasatinib) avoids interactions with proton pump inhibitors (PPIs), making it potentially the first and only dasatinib to provide patients... ► Artikel lesen | |
| 19.07.23 | Nasdaq Stockholm AB: New equity right for trading, Xspray Pharma AB (92/23) | 515 | GlobeNewswire | At the request of Xspray Pharma AB (publ), Xspray Pharma AB (publ) equity
rights will be traded on Nasdaq Stockholm as from 20 July 2023.
Security name: XSPRAY TO5
----------------------------
Short... ► Artikel lesen | |
| 14.07.23 | Nasdaq Stockholm AB: Last day of trading in paid subscription units (BTU) of Xspray Pharma AB (91/23) | 389 | GlobeNewswire | Trading in Xspray Pharma AB paid subscription units is to cease. The last
trading day is July 17, 2023.
Short name: XSPRAY BTU
---------------------------
ISIN code: SE0020355667
---------------------------
Orderbook... ► Artikel lesen | |
| 08.06.23 | Nasdaq Stockholm AB: Listing of subscription units and paid subscription units of XSpray Pharma AB | 397 | GlobeNewswire | With effect from June 09, 2023, the subscription rights in Nasdaq will be
traded on the list for Equity rights. Trading will continue up until and
including June 20, 2023.
Instrument: Subscription... ► Artikel lesen | |
| 02.06.23 | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.06.2023 | 712 | Xetra Newsboard | Das Instrument 6XP SE0009973563 XSPRAY PHARMA AB EQUITY wird cum Kapitalmassnahme gehandelt am 02.06.2023 und ex Kapitalmassnahme am 05.06.2023 The instrument 6XP SE0009973563 XSPRAY PHARMA AB EQUITY... ► Artikel lesen | |
| 04.05.23 | XSpray Pharma AB: Interim Report First Quarter 2023 | 211 | GlobeNewswire (Europe) | January-March 2023, GroupNet sales amounted to SEK 0 thousand (0)Loss before tax amounted to SEK -34,827 thousand (-18,934)Earnings per share before dilution amounted to SEK -1.54 (-0.92)Cash flow from... ► Artikel lesen |
10 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 9,640 | -32,02 % | Allianz, Evotec, Nel ASA, Nordex, TUI - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| QIAGEN | 38,575 | -0,89 % | Biotech Report: Evotec und Qiagen behauptet, US-Sektor verliert | (shareribs.com) Frankfurt / New York 18.04.2024 - Biotech-Aktien zeigen sich im freundlichen Handel uneinheitlich. Evotec und Qiagen notieren etwas fester. An der Wall Street geben Gilead Sciences und... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,940 | 0,00 % | Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX | ||
| VERA THERAPEUTICS | 39,950 | 0,00 % | Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf am Vortag dürften sich die US-Börsen am Donnerstag stabilisieren. Am Mittwoch hatte eine überraschend hohe Inflation im Monat März die Hoffnungen... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 15,190 | 0,00 % | Day One Biopharmaceuticals, Inc.: Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor | First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation RAPNO LGG overall response rate... ► Artikel lesen | |
| ARCELLX | 52,82 | 0,00 % | Should You Be Bullish on Arcellx (ACLX)? | ||
| ARVINAS | 32,540 | 0,00 % | Arvinas Inc.: Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer | ||
| KEROS THERAPEUTICS | 56,24 | +1,90 % | Prozessmanagement in der Gemeinschaftsverpflegung / Keros Consult optimiert Warenwirtschaft für Eichhof-Stiftung Lauterbach | Düsseldorf (ots) - Ab sofort unterstützt Keros Consult, eine hundertprozentige Tochtergesellschaft der Klüh-Gruppe, die Eichhof-Stiftung Lauterbach bei der Optimierung ihrer Bestell- und Produktionsprozesse... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 25,090 | -0,20 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, April 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 46,540 | -6,49 % | Apogee Therapeutics, Inc.: Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases | Preclinical data with APG808 demonstrate the potential for improved dosing over other treatment options in development, including the potential for dosing every six- or eight- weeks compared to dosing... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 43,380 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | ||
| IMMUNOVANT | 28,800 | +0,66 % | Should You Hold Immunovant (IMVT)? | ||
| ADMA BIOLOGICS | 6,460 | -1,22 % | ADMA Biologics, Inc.: ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV & BIVIGAM | FDA Approval Provides for Room Temperature (25°C) Storage Conditions for up to 4 Weeks at Any Point During the 36-Month Approved Shelf Life Extends the Prior Room Temperature Storage Allowance for... ► Artikel lesen | |
| NUVALENT | 67,20 | -0,59 % | Jefferies starts Nuvalent at buy, cites lung cancer drug candidates | ||
| 4D MOLECULAR THERAPEUTICS | 24,250 | 0,00 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis | Conducted initial pivotal study interactions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA); Company has clear registration path for 4D-710 for treatment of cystic... ► Artikel lesen |
Das Unternehmen XSPRAY PHARMA AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,60 % bei einem Aktienkurs von 3,295 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
